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Abstract
Background: The orally administered spherical carbon adsorbent AST-120 is used on-label in Asian countries to
slow renal disease progression in patients with progressive chronic kidney disease (CKD). Recently, two multinational,
randomized, double-blind, placebo-controlled, phase 3 trials (Evaluating Prevention of Progression in Chronic Kidney
Disease [EPPIC] trials) examined AST-120’s efficacy in slowing CKD progression. This study assessed the efficacy
of AST-120 in the subgroup of patients from the United States of America (USA) in the EPPIC trials.
Methods: In the EPPIC trials, 2035 patients with moderate to severe CKD were studied, of which 583 were from the
USA. The patients were randomly assigned to two groups of equal size that were treated with AST-120 or placebo
(9 g/day). The primary end point was a composite of dialysis initiation, kidney transplantation, or serum creatinine
doubling.
Results: The Kaplan-Meier curve for the time to achieve the primary end point in the placebo-treated patients from
the USA was similar to that projected before the study. The per protocol subgroup analysis of the population from the
USA which included patients with compliance rates of ≥67 % revealed a significant difference between the treatment
groups in the time to achieve the primary end point (Hazard Ratio, 0.74; 95 % Confidence Interval, 0.56–0.97).
Conclusions: This post hoc subgroup analysis of EPPIC study data suggests that treatment with AST-120 might delay
the time to primary end point in CKD patients from the USA. A further randomized controlled trial in progressive CKD
patients in the USA is necessary to confirm the beneficial effect of adding AST-120 to standard therapy regimens.
Trial registration: ClinicalTrials.gov NCT00500682; NCT00501046.
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Background
Treatment of end-stage renal disease (ESRD) is costly, and
the prevalence of ESRD is increasing worldwide [1, 2]. The
number of ESRD cases per year with diabetes as the pri-
mary cause has risen since 1980, with 50,000 ESRD cases in
2009 in the United States of America (USA) [2]. The preva-
lence of diabetes in ESRD cases in 2012 was 44 % [2].
Diabetic nephropathy occurs in 20–40 % of patients with
diabetes and is the single leading cause of ESRD [3]. Clearly,
preventing or slowing the progression of CKD and diabetes
may reduce the cost of ESRD treatment considerably [4–7].
Current guidelines focus on managing factors that can has-
ten the progression of CKD, such as hypertension and pro-
teinuria [8–10]. Although angiotensin-converting enzyme
inhibitors (ACEIs) and angiotensin II receptor blockers
(ARBs) slow the progression of CKD, many patients pro-
gress to ESRD despite taking these drugs. Because various
pathologies contribute to the progression of CKD, add-
itional interventions to decelerate the progression of CKD
are needed.
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AST-120 (Kureha Corporation, Tokyo, Japan) is an
orally administered spherical carbon adsorbent approved
in Japan for delaying the initiation of dialysis and ameli-
orating uremia symptoms in patients with progressive
CKD [11, 12]. AST-120 has also been approved in Korea,
the Philippines, and Taiwan. AST-120 reduces the con-
centrations of indoxyl sulfate (IS), a uremic toxin that
enhances CKD progression, in the systemic circulation.
AST-120 lowers IS levels by preventing the absorption
of indole, a tryptophan breakdown product and a pre-
cursor of IS, from the gastrointestinal tract, which is the
presumed mechanism underlying AST-120’s effect of
slowing the progression of CKD [13].
Recently, two large, multinational, randomized,
double-blind, placebo-controlled, phase 3 trials (Evaluat-
ing Prevention of Progression in Chronic Kidney Disease
[EPPIC-1 and EPPIC-2]) were conducted to assess the
effect of AST-120 in adults with CKD treated with
standard therapies. The benefit of adding AST-120 to
the standard therapy in patients with moderate to severe
CKD was not supported by the results of the primary
analysis of the intent-to-treat (ITT) population for each
EPPIC trial or by the result of the pooled analysis of the
two EPPIC trials [14]. We observed that disease progres-
sion in the EPPIC trial placebo population was more
gradual than that estimated during study planning as re-
ported previously [14]. In contrast, pre-specified sub-
group analysis suggested that the population from the
USA showed the expected primary event rate. Therefore,
in this paper, we compared the end point rate and the
disease progression among countries, and we conducted
a post hoc subgroup analysis of the patients from the
USA who were included in the EPPIC trials (EPPIC-
USA), hypothesizing that they would be more likely to
show a response to AST-120 administration.
Methods
Study design
Details of the EPPIC trials have been previously pub-
lished including the patient flow diagram [14]. The pro-
tocols for the EPPIC trials were approved by local ethics
committees, and the trials were conducted in accordance
with Good Clinical Practice Guidelines of the Inter-
national Conference on Harmonisation, the Declaration
of Helsinki, and the European Union Clinical Trials
Directive 2001/20/EC. The EPPIC trials were conducted
between July 2007 and February 2012 at 239 inter-
national sites to compare the effects of AST-120 with
those of placebo on renal outcomes in patients with
moderate to severe CKD receiving standard therapy.
Patients were randomly assigned to groups of equal size
that were treated with 9 g/day AST-120 or placebo.
AST-120 (provided as ten 300-mg capsules 3 times daily)
or placebo was administered with meals and at least 1 h
after concomitant medication. The trials were registered
on ClinicalTrials.gov (NCT00500682 [EPPIC-1] and
NCT00501046 [EPPIC-2]).
Patients
Eligible patients were adults with moderate to severe
CKD (defined as serum creatinine (sCr) at screening of
2.0–5.0 and 1.5–5.0 mg/dL for men and women, re-
spectively) who were not expected to require dialysis or
renal transplantation within 6 months of trial entry and
who were expected to survive for ≥1 year. All patients
were required to have proteinuria or progressive deteri-
oration in renal function indicated by either a urinary
total protein to urinary creatinine (UP/UCr) ratio >0.5 at
screening or an sCr level that had increased by >10 % at
a second evaluation conducted 3 months after screening.
Outcomes
The primary end point was a triple composite of the
time from the date of group assignment to the date of
kidney disease progression, as indicated by dialysis initi-
ation, kidney transplantation, or doubling of the sCr
level, whichever occurred first.
Statistical analysis
The pre-specified statistical methods used for the EPPIC
trials’ analyses were applied in the same manner for
these post hoc subgroup analyses. A pooled population
of both EPPIC trials was used for all analyses. The pri-
mary end point was analyzed using a stratified Cox
proportional hazards regression model with a 95 % con-
fidence interval (CI), and Kaplan-Meier (K-M) method-
ology was used to calculate the median time from group
assignment to renal disease onset. The unstratified Cox
regression method was used to analyze the individual
components of the composite end point. The covariate
adjustments were CKD etiology (diabetic or non-diabetic
nephropathy) and baseline sCr level (greater than or less
than 3 mg/dL) in all analysis, and region (North Amer-
ica, Latin America, or Europe) was added for the all
country primary analysis The unstratified Cox regression
method was used to analyze the primary end point
within the following baseline subgroups: diabetic ne-
phropathy, sCr level, CKD stage determined by the esti-
mated glomerular filtration rate (eGFR) level, C-reactive
protein (CRP) level, anemia status, age, race, gender, use
of ACEI or ARB at baseline, and UP/UCr ratio. Declines
in eGFR were calculated for the first 96-week treat-
ment period to elucidate the degree of renal disease
progression.
The ITT population included all randomly assigned
patients who received at least one dose of the study drug
and had at least one post-baseline sCr measurement.
The per protocol (PP) population included all patients in
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the ITT population without major protocol violations
which were: receiving treatment other than that ori-
ginally assigned, having a treatment compliance rate
of <67 %, and/or a treatment period of <8 weeks. In-
clusion in the PP population was determined during a
blinded data review conducted prior to locking of the
database and study unblinding. Patients who did not
reach the primary end point were censored at the
date of last contact. Sensitivity analyses of the
primary efficacy end point were performed to evaluate
the robustness of the results to censoring patterns.
Results
The number of patients, primary end point rates,
median time to the primary end point, eGFR decline,
and eGFR at dialysis initiation by country are summa-
rized in Table 1. While the median time to the
primary end point pre-study was estimated to be
Table 1 Primary efficacy end point achievement and disease progression by country (pooled ITT population)
Country AST-120 Placebo Placebo
N n (%) N n (%) Median Time a eGFR decline b eGFR at Dialysis Initiation c
ALL 1000 350 (35.0) 999 360 (36.0) 180.1 −4.96 ± 9.50 10.47 ± 5.28
NA CAN 61 22 (36.1) 57 19 (33.3) ND −6.25 ± 9.56 10.65 ± 3.28
USA 290 120 (41.4) 293 129 (44.0) 135.6 −4.66 ± 11.42 13.95 ± 5.84
LA ARG 73 20 (27.4) 73 27 (37.0) 135.7 −5.17 ± 7.69 9.15 ± 2.47
BRA 84 26 (31.0) 83 25 (30.1) ND −3.13 ± 6.65 8.82 ± 3.39
MEX 58 21 (36.2) 57 18 (31.6) ND −5.13 ± 8.35 7.45 ± 3.57
EU CZE 21 6 (28.6) 20 5 (25.0) ND −3.52 ± 3.02 11.91 ± 1.86
DEU 7 2 (28.6) 8 4 (50.0) 119.3 −3.49 ± 14.93 14.77 ± 3.29
ESP 8 3 (37.5) 9 5 (55.6) 71.3 −4.20 ± 4.12 9.08 ± 1.24
FRA 17 5 (29.4) 15 4 (26.7) ND −3.93 ± 7.59 11.24 ± 2.68
ITA 8 4 (50.0) 7 2 (28.6) ND −2.60 ± 2.60 8.18 ± 1.80
POL 36 18 (50.0) 38 15 (39.5) ND −3.50 ± 6.97 10.00 ± 3.23
RUS 173 57 (32.9) 174 51 (29.3) ND −4.78 ± 7.73 7.32 ± 2.90
UKR 164 46 (28.0) 165 56 (33.9) ND −7.17 ± 10.55 5.72 ± 2.67
aWeeks, bmL/min/1.73 m2/year, cmL/min/1.73 m2
ND Not detected
NA North America, LA Latin America, EU Europe, CAN Canada, USA United States of America, ARG Argentina, BRA Brazil, MEX Mexico, CZE Czech Republic, DEU
Germany, ESP Spain, FRA France, ITA Italy, POL Poland, RUS Russia, UKR Ukraine
Fig. 1 Kaplan-Meier plots of primary end point achievement in placebo-treated USA and outside USA populations. CI confidence interval, HR hazard ratio
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124 weeks, the actual time for the entire population
was 180.1 weeks. The median time to the primary
end point could be calculated only for patients from
the USA (135.6), Argentina (135.7), Germany (119.3),
and Spain (71.3). Of the countries for which the ana-
lysis was possible, the USA had the largest study
population (AST-120, N = 290; placebo, N = 293).
The K-M curve for time to the primary end point for
placebo-treated EPPIC-USA patients was similar to the
curve estimated during study planning, while the curve
for the placebo-treated non-USA patients differed sig-
nificantly, as shown in Fig. 1. Therefore, we selected the
EPPIC-USA population to assess the effect of AST-120
in patients with CKD.
Demographics and baseline clinical characteristics of
EPPIC-USA patients are shown in Table 2. Sixty percent
of the EPPIC-USA patients were diabetic and 80 % of
the EPPIC-USA patients were taking an ACEI or an
ARB at baseline data collection. There were no signifi-
cant differences in demographics and baseline clinical
characteristics between the AST-120 and placebo
groups. We applied the pre-specified statistical methods
used in the EPPIC trials [14] to the EPPIC-USA
population.
The results of the primary and secondary analyses,
including the sensitivity analyses, are shown in Fig. 2.
While there was no significant difference in primary end
point achievement between the treatment arms in the
EPPIC-USA ITT population (hazard ratio (HR), 0.82;
95 % CI, 0.64–1.05; P = 0.117), treatment with AST-120
reduced the risk of achieving the primary end point in
the PP population censored at last contact (HR, 0.74;
95 % CI, 0.56–0.97; P = 0.029). K-M curves for the ITT
and PP populations are shown in Fig. 3a and b,
respectively.
In the EPPIC-USA population, the majority of the pri-
mary end points were ESRD (defined as dialysis and
transplantation), while doubling of sCr occurred infre-
quently. In the PP population, treatment with AST-120
reduced the risk of achieving ESRD (HR, 0.70; 95 % CI,
0.53–0.94; P = 0.016) (Fig. 2). The K-M curves for these
results are shown in Fig. 3c.
In the subgroup of patients with diabetic nephropathy
indicated as the CKD etiology, there was a significant
difference in the time to primary end point (HR, 0.70;
95 % CI, 0.49–0.99; P = 0.041) and the time to ESRD
(HR, 0.65; 95 % CI, 0.45–0.93; P = 0.019) between the
AST-120 and placebo groups in the PP population, but
there were no significant differences in the time to pri-
mary end point in the diabetic nephrology ITT popula-
tion (HR, 0.77; 95 % CI, 0.57–1.06; P = 0.106) (Fig. 2).
The K-M curves for these results are shown in Fig. 3e, f,
and d, respectively. These results were similar to that of
the whole population (Fig. 2, ALL).
Table 2 Demographic and baseline clinical characteristics of the
EPPIC-USA population (pooled ITT population)
AST-120 Placebo P-value
N = 290 N = 293
Age, years, mean ± SD 60.1 ± 14.3 61.7 ± 12.3 0.15
Sex, %
Male 64.5 70.6 0.11
Race, %a
White 66.6 60.8 0.51
Black or African American 19.7 25.3
Asian 6.2 5.1
Native Hawaiian or other Pacific
Islander
0.7 0.7
American Indian or Alaska Native 0.0 0.3
Other 6.9 7.8
CKD etiology, %
Diabetic nephropathy 58.6 61.8 0.44
Type I Diabetes 6.2 3.4
Type II Diabetes 52.4 58.4




Use of ACEI or ARB, %
Yes 79.7 80.5 0.79
Baseline sCr, mg/dL, mean ± SDb 3.01 ± 0.84 3.08 ± 0.80 0.28
Baseline eGFR, mL/min/1.73 m2,
mean ± SD
23.59 ± 7.79 23.04 ± 6.92 0.36
Baseline UP/UCr ratio
N 288 292 0.06
Mean ± SD 1.94 ± 1.29 2.15 ± 1.40
CKD stage, %
Stage 3a 0.3 0.7 0.70
Stage 3b 20.7 14.3
Stage 4 64.5 74.4
Stage 5 14.5 10.6
Baseline anemia status, %c
Yes 76.2 79.9 0.25
BMI, kg/m2d
N 289 293 0.20
Mean ± SD 31.8 ± 7.2 32.7 ± 8.7
aRace was self-reported
bTo convert sCr from mg/dL to mol/L, multiply by 88.4
cAnemia was defined as a hemoglobin level <13.5 g/dL (men) or
<12.0 g/dL (women)
dBody mass index is the weight in kilograms divided by the square of the
height in meters
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The results of the subgroup analysis are shown in
Fig. 4. Treatment with AST-120 reduced the risk of
achieving the primary end point in the white (in race)
and ACEI/ARB treatment-receiving patient subgroup. A
tendency was observed that AST-120 treatment delays
the time to primary end point in patients with DN, with
CKD stage 5 and CRP levels (>3.0 mg/L). No effect was
observed in other baseline parameters and demographic
characteristics including age and gender.
Discussion
This post hoc analysis of EPPIC studies in CKD patients
from 13 countries demonstrated that the occurrence of
primary end point, that is the composite of dialysis initi-
ation, kidney transplantation, and serum creatinine
doubling, was different among countries. Particularly,
the time to primary end point in the EPPIC-USA pla-
cebo population was shorter than that of the placebo
population outside the USA (P < 0.001). The incidence
rates of ESRD continue to become clear based on the
enhancement of renal databases in each countries and
regions. However, the international difference of CKD
progression and time to ESRD of CKD patients have not
well discussed and remain unclear.
Recently, the National Kidney Foundation (NKF) and
Food and Drug Administration (FDA) published a series
of reports showing that eGFR decline associated with
ESRD occurrence [15–18]. However, the value of eGFR
decline in the EPPIC-USA placebo population did not
differ from that in EPPIC overall population. The time
to end point achievement by each country was not
related to the observed eGFR decline in the EPPIC
population. Thus, the difference in ESRD occurrence
among the countries could not be attributed to differ-
ences in eGFR decline. Other possible causes may be as-
sumed as following.
First, regional differences in the mean eGFR at dialysis
could have contributed to the time to primary end point.
Of the countries participating in the EPPIC trials, the
USA had the highest mean eGFR at dialysis (13.53 ±
5.68 mL/min/1.73 m2), which was close to the K/DOQI
criterion of 15 mL/min/1.73 m2 [19]. This observation is
consistent with data from the US Renal Data System
(USRDS), which shows that >15 % of patients started
dialysis with an eGFR of ≥15 mL/min/1.73 m2 after 2009
[2]. The median eGFR at the start of dialysis was
7.7 mL/min/1.73 m2 in the 2003 European Renal
Association-European Dialysis and Transplant Associ-
ation Registry [20], notably lower than that in USRDS.
Regional differences may account for the observation
that the majority of the primary end points were ESRD
in the EPPIC-USA population.
Second, the dietary habit and nutritional status are
variety among countries and it has been proposed that
Fig. 2 Achievement of primary and secondary end points in the EPPIC-USA subpopulation. a Sensitivity analyses of the primary efficacy end point
were performed to evaluate the robustness of the results to censoring patterns. b First occurrence of dialysis, kidney transplantation, or doubling
of sCr in the 84 days after the last sCr assessment or last dose. Patients who did not have an event in this period were censored at the last sCr
assessment. CKD chronic kidney disease, DN diabetic nephropathy, ESRD end stage renal disease, HR hazard ratio, ITT intent-to-treat, PP
per protocol, sCr serum creatinine
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they could affect the CKD progression. The role of nu-
trition in the progression of CKD is unclear with dis-
crepancies between various studies performed, but some
reviews suggested that dietary protein intake [21] and
obesity [22] are risk factors for CKD. In EPPIC studies,
nutritional information was not collected. However the
demographic parameter of patients showed that the
mean of body mass index (BMI) and diabetes ratio of
USA patients was higher than that of patients outside
the USA at baseline (p <0.001). These could relate to the
time to renal events.
The difference in event rates observed between coun-
tries may have also been due to the influence of differing
healthcare standards and guidelines. Prior to study start,
we estimated the primary end point rate for a placebo
population based on RENAAL study data; in that study,
45 % of study patients were from the US [23]; we found
the median time to primary end point of EPPIC-USA
placebo population was similar to the estimated median
time of placebo population in the RENNAL study.
A trend for a beneficial effect of AST-120 was ob-
served in the EPPIC-USA PP population comprised of
patients who took the study medication as prescribed,
had study drug compliance rates ≥67 %, and were
treated for at least 8 weeks. This effect was corroborated
by sensitivity analyses that assessed the time lag be-
tween treatment cessation and event occurrence.
Therefore, good patient compliance highly determines
the positive effect of AST-120 in preventing systemic
accumulation of uremic toxins, an important factor
considering the 30 capsule per day regimen. The diffi-
culty of AST-120 medication may be an issue needing
to be solved as relatively large number of capsule
should be taken. AST-120 treatment was beneficial in
patients with diabetic nephropathy; however, for
patients with an etiology other than diabetic nephrop-
athy, there was no difference between the AST-120-
treated and placebo groups. We speculate that the
difference in etiology is responsible for the difference
in event rates between the placebo groups with dia-
betic nephropathy and non-diabetic nephropathy (47.5
vs. 38.4 %, respectively). Results from an additional
subgroup analysis in ACEI- or ARB-treated patients
suggested that the addition of AST-120 to standard
therapy produced therapeutic benefits by a distinct
mechanism of action that involved lowering levels of
uremic toxins such as IS [24].
In addition, examining the use of AST-120 in popu-
lations that have a particular rate of disease progres-
sion, such as diabetic nephropathy patients or ESRD
Fig. 3 Kaplan-Meier plots of primary end point achievement in the EPPIC-USA population. a ITT primary end point censored at last contact,
b PP primary end point censored at last contact, c PP ESRD censored at last contact, d ITT DN primary end point censored at last
contact, e PP DN primary end point censored at last contact, f PP DN ESRD censored at last contact. DN diabetic nephropathy, ESRD
end stage renal disease, ITT intent-to-treat, PP per protocol
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patients with residual renal function, may be useful.
Atoh et al. reported a strong correlation between IS
serum levels and eGFRs [25]. The EUTox group re-
ported that IS serum levels were increased signifi-
cantly and progressively as patients progressed
through the stages of CKD, including predialysis and
hemodialysis patients [26].
Conclusions
This post hoc subgroup analysis of EPPIC study data
suggests that treatment with AST-120 might delay
the time to primary end point in CKD patients from
the USA. The major limitations of this analysis are
its post hoc nature and its use of one subgroup
population. The conclusions of this study are
hypothesis-generating only, and the p-values should
not be interpreted by the usual standards regarding a
Type-1 error threshold of 0.05. According to our
findings, a randomized controlled trial in progressive
CKD patients in the USA is necessary to confirm the
beneficial effect of adding AST-120 to standard ther-
apy regimens.
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